Cargando…

Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols

Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alviggi, Carlo, Humaidan, Peter, Ezcurra, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299595/ https://www.ncbi.nlm.nih.gov/pubmed/22309877 http://dx.doi.org/10.1186/1477-7827-10-9

Ejemplares similares

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
por: Ezcurra, Diego, et al.
Publicado: (2014)

Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins
por: Andersen, Claus Y, et al.
Publicado: (2014)

Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients
por: Bosch, Ernesto, et al.
Publicado: (2011)

Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials
por: Conforti, Alessandro, et al.
Publicado: (2021)

Biological versus chronological ovarian age: implications for assisted reproductive technology
por: Alviggi, Carlo, et al.
Publicado: (2009)

Individualized controlled ovarian stimulation in expected poor-responders: an update
por: Haahr, Thor, et al.
Publicado: (2018)

Genetic Variants of Gonadotropins and Their Receptors Could Influence Controlled Ovarian Stimulation: IVF Data from a Prospective Multicenter Study
por: Alviggi, Carlo, et al.
Publicado: (2023)

Pharmacogenomic Biomarkers of Follicle-Stimulating Hormone Receptor Malfunction in Females with Impaired Ovarian Response—A Genetic Survey
por: Tafazoli, Alireza, et al.
Publicado: (2021)

Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF
por: Huang, Jialyu, et al.
Publicado: (2019)

The Role of Growth Hormone on Ovarian Functioning and Ovarian Angiogenesis
por: Devesa, Jesús, et al.
Publicado: (2019)

A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology
por: Alviggi, Carlo, et al.
Publicado: (2013)

Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?
por: Lispi, Monica, et al.
Publicado: (2023)

Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment
por: Fiedler, Klaus, et al.
Publicado: (2012)

Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis
por: Lehert, Philippe, et al.
Publicado: (2010)

The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome
por: Humaidan, Peter, et al.
Publicado: (2016)

Reply: Questionable recommendation for LPS for IVF/ICSI in ESHRE guideline 2019: ovarian stimulation for IVF/ICSI
por: Broekmans, Frank, et al.
Publicado: (2021)

The Impact of Genetic Variation and Gene Expression Level of The Follicle-Stimulating Hormone Receptor on Ovarian Reserve
por: Ghezelayagh, Zeinab, et al.
Publicado: (2018)

Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus
por: Conforti, Alessandro, et al.
Publicado: (2022)

Anti Mullerian Hormone: Ovarian response indicator in young patients receiving Long GnRH Agonist Protocol for Ovarian Stimulation
por: Jamil, Zehra, et al.
Publicado: (2016)

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation
por: Raju, Gottumukkala Achyuta Rama, et al.
Publicado: (2013)

Profile of follicle-stimulating hormone and polymorphism of follicle-stimulating hormone receptor in Madrasin cattle with ovarian hypofunction
por: Utomo, Budi, et al.
Publicado: (2020)

Exploring the Impact of Controlled Ovarian Stimulation and Non-Invasive Oocyte Assessment in ART Treatments
por: Sciorio, Romualdo, et al.
Publicado: (2023)

Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone
por: Jamil, Zehra, et al.
Publicado: (2016)

Live birth after letrozole as an adjunct to follicle-stimulating hormone versus follicle-stimulating hormone alone for ovarian stimulation in in vitro fertilisation cycles—study protocol for a randomised controlled trial
por: Guo, Wei, et al.
Publicado: (2022)

Management Strategies for POSEIDON Groups 3 and 4
por: Haahr, Thor, et al.
Publicado: (2019)

ESHRE guideline: ovarian stimulation for IVF/ICSI(†)
por: Bosch, Ernesto, et al.
Publicado: (2020)

The SUPER study: protocol for a randomised controlled trial comparing follicle-stimulating hormone and clomiphene citrate for ovarian stimulation in intrauterine insemination
por: Danhof, NA, et al.
Publicado: (2017)

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
por: Rabati, Behnaz Khani, et al.
Publicado: (2012)

What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?
por: Knez, Jure, et al.
Publicado: (2015)

Ovarian stimulation with luteinizing hormone supplementation: the impact of timing on ovarian response and ICSI outcomes
por: Setti, Amanda, et al.
Publicado: (2023)

Gonadotropin releasing hormone analogs as part of controlled ovarian stimulation
por: Fleming, Richard
Publicado: (2022)

The ratio of exogenous Luteinizing hormone to Follicle stimulating hormone administered for controlled ovarian stimulation is associated with oocytes’ number and competence
por: Albu, Dragos, et al.
Publicado: (2020)

Future Perspectives of POSEIDON Stratification for Clinical Practice and Research
por: Humaidan, Peter, et al.
Publicado: (2019)

Editorial: POSEIDON’s Stratification of ‘Low Prognosis’ Patients in ART: The WHY, the WHAT, and the HOW
por: Esteves, Sandro C., et al.
Publicado: (2021)

LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women
por: Marchiani, S., et al.
Publicado: (2020)

Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations
por: Abu-Musa, Antoine, et al.
Publicado: (2020)

Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI
por: Bosch, Ernesto, et al.
Publicado: (2020)

Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era: A Meta-analysis
por: Santi, Daniele, et al.
Publicado: (2017)

Molecular mechanisms of incretin hormone secretion()
por: Ezcurra, Marina, et al.
Publicado: (2013)

Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations
por: Zhou, Ruiqiong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ns2ehmhtl3q8l5vlq9fq6a60n